FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

Г											
	OMB APPROVAL										
ı											
l	OMB Number:	3235-0287									
l	Estimated average burden										
l	hours per response	0.5									

	Check this box if no longer subject
	to Section 16. Form 4 or Form 5
\Box	obligations may continue. See
	Instruction 1(b).

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

Name and Address of Reporting Person* Jones Jeffrey Alan						2. Issuer Name and Ticker or Trading Symbol Cullinan Oncology, Inc. [CGEM]									ationship of Reporting k all applicable) Director Officer (give title			erson(s) to Is 10% Ov Other (s	vner
(Last)	`	irst) (I	Middle)		3. Date of Earliest Transaction (Month/Day/Year) 05/18/2023									X	belov			below)	вреспу
ONE MAIN STREET, SUITE 1350						4. If Amendment, Date of Original Filed (Month/Day/Year)							r)	6. Individual or Joint/Group Filing (Check Applic Line)					.
(Street) CAMBRIDGE MA 02142														Λ	X Form filed by One Reporting Person Form filed by More than One Reporting Person				
(City) (State) (Zip)						Rule 10b5-1(c) Transaction Indication													
						Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.											ended to		
		Table	l - No	n-Derivat	tive S	ecui	ities	Acq	uired,	Dis	oosed of	, or I	3enefi	ciall	y Owr	ned			
1. Title of Security (Instr. 3) 2. Transacti Date (Month/Day					y/Year) Execu		Deemed cution Date, y nth/Day/Year)		Transaction Disposed Code (Instr. 5)		ties Acquired (A I Of (D) (Instr. 3		, 4 and Secu		cially I	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)		7. Nature of Indirect Beneficial Ownership (Instr. 4)	
									Code	v	Amount	(A) (D)	or Pri	ce	Report Transa	rted action(s) . 3 and 4)			
Common Stock 05/18/2						2023			S		394(1)	I	\$	8.76	58	58,824		D	
	Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)																		
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	rcise (Month/Day/Year) Execution Date, if any (Month/Day/Year)			4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)			7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4		8. Price of Derivativ Security (Instr. 5)		9. Number derivative Securities Beneficiall Owned Following Reported Transactio (Instr. 4)	Owne Form: Direct or Ind (I) (Ins	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
					Code	v	(A)	(D)	Date Exercisa		Expiration Date			r					

Explanation of Responses:

1. Sale of shares to cover personal income tax obligations upon vesting of restricted stock units.

Remarks:

/s/ Jacquelyn Sumer, Attorney-in-Fact 05/19/2023

** Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.